Short answer
Vaxcyte, Inc. (PCVX) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$297M
- −39.6% YoY · −4.5% QoQ
- EPS (diluted)
- −$1.99
- −26.8% YoY · −1.5% QoQ
Source: XBRL data from the Vaxcyte, Inc. (PCVX) Q3 2026 10-Q on SEC EDGAR. USD.
Vaxcyte, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved products or commercial sales
- Net loss $297.1M vs $212.8M YoY, operating loss $308.3M vs $242.4M
- R&D expense $270.3M, up 28.8% YoY, driven by PCV manufacturing and OPUS trials
- Cash, equivalents and investments $2.3B, including $0.1B cash and $2.1B investments
- Operating cash outflow $737.2M; October offerings generated approximately $1.15B gross proceeds, outlook funding through at least 12 months
Risk Factors
- Newly added AI risk: expanded operational use of AI could trigger privacy-law violations, regulatory scrutiny, or reputational harm
- Most materially updated regulatory risk: FDA may require expanded trials, additional safety data, or post-marketing surveillance for vaccine approvals
- Regulatory compliance risk: federal vaccine-policy changes could alter ACIP-linked coverage, reimbursement, liability protections, and state mandates
- Competitive risk: Pfizer plans PCV25 pediatric Phase 3 completion in Q2 2029, with regulatory submission planned in 2029
- Liquidity risk: $2.3 billion cash, cash equivalents, and investments expected to fund operations for at least 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vaxcyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.